Key Highlights

  • Genmab shares are trading at $38.79 in Monday's session, up 11.63%, on Volume more than four times average.
  • The Phase 3 EPCORE DLBCL-2 trial showed epcoritamab plus R-CHOP reduced the risk of disease progression or death by 51% in newly diagnosed diffuse large B-cell lymphoma.
  • Earlier in the session, new Rina-S ovarian cancer data and a round of higher price targets had already lifted the shares.
  • Investors next watch petosemtamab data at the ESMO meeting from October 23 to 27 and third-quarter results on November 5.

Two Catalysts Stack Up in One Session

Genmab (NASDAQ:GMAB), the Copenhagen-based antibody company whose science powers eight approved medicines, is surging in Monday's session. The shares are up 11.63% at $38.79 on volume more than four times average, while the healthcare sector is little changed.

The first lift came from new data for Rina-S, its ovarian cancer drug, and a wave of price-target increases. A second leg followed when Genmab and AbbVie (NYSE:ABBV) announced positive topline Phase 3 results for epcoritamab in newly diagnosed lymphoma.

EPCORE DLBCL-2 Sets a First for Bispecifics in Frontline Lymphoma

The trial tested fixed-duration epcoritamab, a subcutaneous T-cell engaging bispecific antibody, added to the standard R-CHOP regimen in patients with newly diagnosed diffuse large B-cell lymphoma and an International Prognostic index score of 2 to 5. The risk of progression or death fell by 51%, with a hazard ratio of 0.49 and a p-value below 0.0001. Safety was consistent with the known profiles of each treatment, and an independent committee recommended unblinding the study after the first planned interim analysis.

The companies called it the first Phase 3 study of a bispecific antibody combination to show a statistically significant progression-free survival gain in frontline disease. The combination is investigational and not approved, and the partners will now engage global regulators.

Rina-S Data Drew the Earlier Bid

At an international gynecologic cancer meeting, a Phase 2 trial of Rina-S in platinum-resistant ovarian cancer showed a 45.9% confirmed response rate among 109 patients, with a median duration of response of 12.1 months and median progression-free survival of 9.5 months. One brokerage raised its target to $54 from $45, another resumed coverage with a bullish view and a $50 target, and a third judged the profile stronger than a rival antibody-drug conjugate, putting peak ovarian sales near $2 billion.

Caveats include the single-arm design and serious adverse events in about a third of patients, and one bank downgraded the stock on valuation.

From ESMO in Late October to Third-Quarter Results on November 5

The calendar is busy. Petosemtamab data are due at the ESMO meeting from October 23 to 27, third-quarter results arrive on November 5, and AbbVie and Genmab will engage global regulators on epcoritamab plus R-CHOP. Full lymphoma data are to be submitted to a future medical meeting.

After the jump to $38.79 the shares sit about 3% below the 52-week high of $40.06 and about 64% above the low of $23.62, so much of the good news is already in the price. The next steps are regulatory feedback and how the full data look when presented.